{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:50:41Z","timestamp":1793922641563,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.ymgme.2008.10.004","type":"journal-article","created":{"date-parts":[[2008,12,4]],"date-time":"2008-12-04T12:37:50Z","timestamp":1228394270000},"page":"4-12","source":"Crossref","is-referenced-by-count":93,"title":["A retrospective analysis of the potential impact of IgG antibodies to agalsidase \u03b2 on efficacy during enzyme replacement therapy for Fabry disease"],"prefix":"10.1016","volume":"96","author":[{"given":"Bernard","family":"B\u00e9nichou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Norfleet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2008.10.004_bib1","series-title":"Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"\u03b1-Galactosidase a deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ymgme.2008.10.004_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2008.10.004_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2008.10.004_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A--replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2008.10.004_bib5","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies","volume":"122","author":"Thurberg","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ymgme.2008.10.004_bib6","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2008.10.004_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of \u03b1-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2008.10.004_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2008.10.004_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase \u03b2 therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2008.10.004_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase \u03b2 therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Int. Med."},{"key":"10.1016\/j.ymgme.2008.10.004_bib11","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2008.10.004_bib12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2008.10.004_bib13","first-page":"II4","article-title":"Immunogenicity of recombinant human proteins: causes and consequences","volume":"251","author":"Schellekens","year":"2004","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2008.10.004_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1529-1049(02)00049-1","article-title":"Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders","volume":"2","author":"Richards","year":"2002","journal-title":"Clin. Appl. Immunol. Rev."},{"key":"10.1016\/j.ymgme.2008.10.004_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V90.1.43","article-title":"Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid \u03b2-glucosidase","volume":"90","author":"Ponce","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2008.10.004_bib16","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymgme.2008.10.004_bib17","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function--measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2008.10.004_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1373\/clinchem.2004.038323","article-title":"Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy","volume":"51","author":"Roddy","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2008.10.004_bib19","first-page":"874","article-title":"Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin+QS21 vaccine: a dose-response study","volume":"6","author":"Chapman","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymgme.2008.10.004_bib20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1542\/peds.105.2.372","article-title":"Late abnormal findings on high-resolution computed tomography after mycoplasma pneumonia","volume":"105","author":"Kim","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2008.10.004_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2008.10.004_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Vedder","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2008.10.004_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2007.06.013","article-title":"Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase \u03b2 therapy","volume":"92","author":"Ohashi","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2008.10.004_bib24","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase \u03b1 and \u03b2","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2008.10.004_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2008.03.008","article-title":"Reduced \u03b1-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease","volume":"94","author":"Ohashi","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2008.10.004_bib26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human \u03b1-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymgme.2008.10.004_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00439-005-1300-5","article-title":"Fabry disease: correlation between structural changes in \u03b1-galactosidase and clinical, and biochemical phenotypes","volume":"117","author":"Matsuzawa","year":"2005","journal-title":"Hum. Genet."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719208002540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719208002540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T20:37:55Z","timestamp":1589315875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719208002540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S1096719208002540"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2008.10.004","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}